SCHEMBL4252480

SCHEMBL4252480

COC(C[N+](C)(C)C)C(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 4/20 0.45
CHRM2 P08172 3/20 0.45
CHRM4 P08173 3/20 0.45
TSHR P16473 2/20 0.45
TBXA2R P21731 2/20 0.45
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
GALR3 O60755 2/20 0.43
BLM P54132 1/20 0.43
LMNA P02545 3/20 0.39
CHRM5 P08912 3/20 0.39
CHRM3 P20309 3/20 0.39
CYP2C9 P11712 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 1/20 0.38
HRH1 P35367 1/20 0.38
SLC22A16 Q86VW1 1/20 0.37
CPT2 P23786 1/20 0.34
CPT1A P50416 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16637634 0.98 MAPT (0.47) CHRM1CHRM2CHRM4TSHRTBXA2R
Bromide SCHEMBL8759877 0.98 CHRM1 (0.43) CHRM1CHRM2CHRM4TSHRTBXA2R
Methacholine SCHEMBL1536636 0.85 TSHR (0.72) CHRM1CHRM2CHRM4TSHRTBXA2R
SCHEMBL4783813 0.79 CHRM1 (0.59) CHRM1CHRM2CHRM4TSHRTBXA2R
SCHEMBL27362812 0.79 LMNA (0.47) CHRM1CHRM2CHRM4TSHRTBXA2R
SCHEMBL6512446 0.79 CHRM1 (0.43) CHRM1CHRM2CHRM4TSHRTBXA2R
Hydrochloric Acid SCHEMBL1759064 0.77 LMNA (0.48) CHRM1CHRM2CHRM4TSHRTBXA2R
Hydrochloric Acid SCHEMBL28364686 0.77 MAPT (0.61) CHRM1CHRM2CHRM4TSHRTBXA2R
Hydrochloric Acid SCHEMBL10633363 0.77 MAPT (0.61) CHRM1CHRM2CHRM4TSHRTBXA2R
Iodide SCHEMBL27443982 0.77 CHRM1 (0.57) CHRM1CHRM2CHRM4TSHRTBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110835614-B Bifidobacterium lactis GKK2, composition containing same and application of composition in improving allergic asthma 葡萄王生技股份有限公司 2023-08-25 CN disclosed
CN-112891397-A Compound essential oil preparation for treating asthma and preparation method and application thereof 江西中医药大学 2021-06-04 CN disclosed
CN-110835614-A Bifidobacterium lactis GKK2, composition containing the same and use thereof for improving allergic asthma 葡萄王生技股份有限公司 2020-02-25 CN disclosed
EP-3030252-A2 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2016-06-15 EP disclosed
WO-2015021358-A2 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT CHARMOT DOMINIQUE (US) 2015-02-12 WO disclosed
US-20140086960-A1 IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES OM PHARMA (CH) 2014-03-27 US disclosed
US-8618080-B2 Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines OM PHARMA (CH) 2013-12-31 US disclosed
US-20120178721-A1 IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES OM PHARMA (CH) 2012-07-12 US disclosed
EP-2051728-A2 IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES OM Pharma (CH) 2009-04-29 EP disclosed
US-20090054378-A1 IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES OM PHARMA (CH) 2009-02-26 US disclosed
WO-2007102081-A2 IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES OM PHARMA (CH) 2007-09-13 WO disclosed
CN-1605349-A Chinese traditional medicine for treating cough and variable asthma after cold and its preparation CHAO ENXIANG (CN) 2005-04-13 CN disclosed
WO-2005030245-A1 INHIBITION OF FRACTALKINE OR OF ITS RECEPTOR FOR THE TREATMENT OF ATOPIC ALLERGIC DISEASES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2005-04-07 WO disclosed
EP-0865419-B1 INDANE DIMER COMPOUNDS AND THEIR PHARMACEUTICAL USE VENANTIUS LTD (IE) 2003-08-06 EP disclosed
US-6300376-B1 FOR THERAPY TO ACHIEVE SMOOTH MUSCLE RELAXING ACTIVITY AND/OR MAST CELL STABILIZING ACTIVITY AND/OR ANTI-INFLAMMATORY ACTIVITY VENANTIUS LIMITED (IR) 2001-10-09 US disclosed
EP-0865419-A1 INDANE DIMER COMPOUNDS AND THEIR PHARMACEUTICAL USE Venantius Limited (IE) 1998-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054378-A1 IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES HRH4, HRH2, HRH3 CHRM1 131/4885CHRM2 125/4885CHRM4 408/4885
US-20140086960-A1 IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES HRH4, HRH2, IFNG CHRM1 100/4885CHRM2 109/4885CHRM4 326/4885
US-20120178721-A1 IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES HRH4, IFNG, HRH2 CHRM1 86/4885CHRM2 101/4885CHRM4 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.